The ABCL635 Phase 1 data is the primary catalyst — clean safety and monthly dosing profile differentiates from approved small molecules (fezolinetant) that require liver monitoring. The Phase 2 readout in Q3 2026 is the next major event. Revenue growth is driven by research fees, not recurring revenue, so focus on pipeline catalysts rather than financials. Cash runway of ~$655M funds operations well beyond 3 years.
Price Chart
Executive Summary
AbCellera reported Q1 2026 revenue of $8.3M (up 96% YoY from $4.2M) and a net loss of $43.2M ($-0.14/share), narrower than the $45.6M loss in Q1 2025. The company also disclosed positive interim Phase 1 data for ABCL635 (NK3R antibody for menopausal hot flashes), showing a favorable safety profile, no liver toxicity, and a 24-day half-life supporting monthly dosing. The Phase 2 readout is expected in Q3 2026.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $8.3M vs $4.2M in Q1 2025 (+96% YoY)
- Net loss of $43.2M ($-0.14/share) vs $45.6M ($-0.15/share) in Q1 2025
- Total available liquidity ~$655M ($531M cash + $124M government funding)
- Positive interim Phase 1 data for ABCL635: no liver toxicity, 24-day half-life, dose-dependent biomarker suppression
- Phase 2 topline readout for ABCL635 expected in Q3 2026
- Partner-led programs with downstreams decreased to 40 from 44 at year-end 2025
- Operating cash burn increased to $33.5M in Q1 2026 from $11.6M in Q1 2025
Financial Impact
Revenue doubled YoY to $8.3M; net loss improved slightly to $43.2M; cash burn increased to $33.5M
Risk Factors
- Phase 2 efficacy data for ABCL635 may not meet expectations
- Partner-led programs declining (44 to 40) signals potential pipeline attrition
- Operating cash burn increasing ($33.5M vs $11.5M in Q1 2025)
- No guidance provided; pre-revenue biotech with uncertain commercialization timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001703057-26-000027 |
| Document: abcl-20260511.htm | 0001703057-26-000027 |
| Document: a2026q1fybusinessupdatem.htm | 0001703057-26-000027 |
| Document: 0001703057-26-000027-index-headers.html | 0001703057-26-000027 |
| Document: 0001703057-26-000027-index.html | 0001703057-26-000027 |
| Document: 0001703057-26-000027.txt | 0001703057-26-000027 |
| 8-K Data (Synthetic) | 0001703057-26-000027 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $10.61 $12.65 | ▲ +19.23% | ▲ +17.91% | $13.74 (+29.50%) |
Aug 18, 2026 6w ago | Insider Cluster | $11.12 $11.67 | ▲ +4.95% | ▲ +6.69% | $13.74 (+23.56%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.20 $11.41 | ▼ −1.88% | ▼ −3.85% | $13.74 (−22.68%) |
Aug 11, 2026 7w ago | 424B5 | $10.36 $10.46 | ▼ −1.01% | ▼ −2.91% | $13.74 (−32.69%) |
Aug 10, 2026 7w ago | 8-K | $9.34 $11.44 | ▲ +22.48% | ▲ +23.40% | $13.74 (+47.11%) |
Jul 29, 2026 9w ago | 8-K | $5.39 $12.24 | ▲ +127.09% | ▲ +122.07% | $13.74 (+154.92%) |
Jul 6, 2026 12w ago | 3 | $7.69 $5.83 | ▼ −24.19% | ▼ −25.52% | $13.74 (+78.67%) |
Jul 6, 2026 12w ago | 8-K | $7.87 $5.71 | ▼ −27.45% | ▼ −26.88% | $13.74 (+74.59%) |
Jun 5, 2026 17w ago | 8-K | $5.62 $7.87 | ▲ +40.04% | ▲ +38.17% | $13.74 (+144.48%) |
May 11, 2026 20w ago | 8-K | $4.95 $5.09 | ▲ +2.83% | ▲ +4.56% | $13.74 (+177.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access